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    In this issue of the Korean journal of anesthesiology, Bae and 
colleagues [1] studied the induction and maintenance dose of 
propofol for anesthesia in major burn patients. They reported 
that an induction dose of 1.5 mg/kg is appropriate and a slow 
infusion rate of 20 mg/kg/hr is safe for maintaining the desirable 
hypnotic condition and this causes no significant hemodynamic 
problems. Many pathophysiologic alterations in patients with 
major burn can cause changes in the response of propofol. 
Many other diseases can change the effect of anesthetic drugs 
in patients. The study of Bae and colleagues [1] would seem to 
reflect the increasing interest of anesthesiologists in clinical 
pharmacologic study. Korean anesthesiologists have recently 
focused on the clinical pharmacologic studies including 
pharmacokinetic/pharmacodynamic (PK/PD) modeling. The 
Korean Society for Intravenous Anesthesia changed its formal 
name to the Korean Society for Anesthetic Pharmacology in 
May 2008. Microemulsion propofol was developed in Korea and 
its induction and recovery characteristics have been evaluated 
[2].
    Historically, modern anesthesia has slowly developed as a 
medical discipline since William Morton first administered 
ether to a patient. But anesthesia today stands out as the major 
primary medical specialty that routinely incorporates clinical 
pharmacology principles into patient care. Anesthesiologists 
have made major contributions to clinical pharmacology in the 
areas of physiological pharmacokinetics, PK-PD modeling and 
pharmacogenetics [3]. Physiologic pharmacokinetic models 
describe the time sequences of the measured blood and tissue 
drug concentrations by apportioning the cardiac output and 
hence the drug distribution, among the tissues with similar 
perfusion and drug solubility characteristics [4]. Brodie et al. 
[5] demonstrated that the effects of small doses of thiopental 
were terminated by redistribution from the site of action to 
other body tissues and not by metabolism. The physiologic 
pharmacokinetic model provides the first understanding of 
factors that contribute the variability in response to rapidly 
acting drugs. PK/PD modeling is the process of constructing 
a mathematical model to relate the time course of the dose 
to the concentration (PK) and the concentration to the effect 
(PD). Minto and Schnider [6] well summarized the enormous 
contribution of PK/PD modeling to advances in intravenous 
anesthesia. They said that PK/PD models have provided us 
with insight into the factors affecting the onset and offset of 
drugs’ effects. The PK/PD model was postulated from the 
most important concept of the “effect compartment” model 
and this concept was developed from the data obtained from 
experiments where a neuromuscular-blocking agent was 
administered [7,8]. The data was modeled to integrate and 
characterized the lag time between the time course of the 
concentration of a drug and the time course of its measured 
effect. This concept was developed under the circumstances 
that patients are routinely and exhaustively monitored during 
anesthesia. This makes it easy to observe and quantify the 
effects of anesthetic drugs.
    Anesthesia has been the benchmark for the development 
of new concepts and principles in clinical pharmacology. 
Using PK/PD modeling techniques from the early phases of 
clinical development has helped to define the characteristics 
of most drugs and specially those drugs that are intravenously 
administered. With the appropriate statistical methodology, 150 www.ekja.org
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the effects of covariate factors have been identified and based 
on all this, rational dosing guidelines have been defined and 
later validated in routine clinical use [9]. For the point of view 
of the clinical pharmacologist, intravenously administered 
anesthetic drugs have concepts and lessons that are valuable for 
drug development. The intravenously administered hypnotic 
and opiate drugs that are used for producing anesthesia 
have fundamental characteristics that are applicable to all 
drug development. These characteristics include the 100% 
bioavailability and a precise knowledge of the administered 
drug dose, easy access to blood sampling, linear PKs, relatively 
rapid onset and offset, a profound degree of drug effect from 
awake to completely unconscious and the ability to directly 
record the drug effects as shown on an electroencephalogram 
[10]. Anesthesiologists have many advantages to gain knowledge 
and data for drug discovery, development, regulation, and 
utilization.
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